Xeris Biopharma (XERS) reported $292M in revenue for fiscal 2025, +43.7% year on year. That ranks #2491 by revenue among 2853 SEC filers and #252 in Healthcare. Net income was $554,000, a net margin of 0.2%. Revenue has grown 70.2% a year on average since 2020 ($20.4M then). The fiscal 2025 balance sheet shows $384M in total assets, $111M in cash and $220M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $292M | +43.7% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $24.9M | +$58.5M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $554,000 | +$55.4M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $28.6M | +$65.6M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.1M | +187.8% | FY20212021-12-31 |
| Total assetsAssets | $384M | +18.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $13.7M | +$43.3M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $111M | +55.0% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $220M | +1.5% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $83.1M | $2.2M | Open → |
| Q2 20262026-06-30 | $92.1M | −$31.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Xeris Biopharma Holdings, Inc.
- Ticker
- XERS
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001867096
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KMar 2, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| EvolusEOLS | $297M | −$51.6M |
| Ironwood PharmaceuticalsIRWD | $296M | $24.0M |
| Rigel PharmaceuticalsRIGL | $294M | $367M |
| Xeris BiopharmaXERS | $292M | $554,000 |
| Aurinia PharmaceuticalsAUPH | $283M | $287M |
| Adaptive BiotechnologiesADPT | $277M | −$59.5M |
| VericelVCEL | $276M | $16.5M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Xeris Biopharma — Key figures |url=https://companiesranked.com/en/company/xeris-biopharma |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Xeris Biopharma — Key figures. CompaniesRanked. https://companiesranked.com/en/company/xeris-biopharmaBibTeX
@misc{companiesranked-en-company-xeris-biopharma-2026,
author = {{CompaniesRanked}},
title = {{Xeris Biopharma — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/xeris-biopharma}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001867096-26-000016 · March 2, 2026
{{cite web |title=Xeris Biopharma — Key figures — 10-K (0001867096-26-000016) |url=https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/xers-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-02}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.